Michael S Magee
Overview
Explore the profile of Michael S Magee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davari K, Holland T, Prassmayer L, Longinotti G, Ganley K, Pechilis L, et al.
J Immunother Cancer
. 2021 Mar;
9(3).
PMID: 33771892
Background: The cancer-testis antigen MAGE-A4 is an attractive target for T-cell-based immunotherapy, especially for indications with unmet clinical need like non-small cell lung or triple-negative breast cancer. Methods: An unbiased...
2.
Magee M, Abraham T, Baybutt T, Flickinger Jr J, Ridge N, Marszalowicz G, et al.
Cancer Immunol Res
. 2018 Apr;
6(5):509-516.
PMID: 29615399
One major hurdle to the success of adoptive T-cell therapy is the identification of antigens that permit effective targeting of tumors in the absence of toxicities to essential organs. Previous...
3.
Xiang B, Baybutt T, Berman-Booty L, Magee M, Waldman S, Alexeev V, et al.
J Immunol
. 2017 Mar;
198(9):3507-3514.
PMID: 28341670
Heterologous prime-boost immunization with plasmid DNA and viral vector vaccines is an emerging approach to elicit CD8 T cell-mediated immunity targeting pathogens and tumor Ags that is superior to either...
4.
Magee M, Kraft C, Abraham T, Baybutt T, Marszalowicz G, Li P, et al.
Oncoimmunology
. 2016 Nov;
5(10):e1227897.
PMID: 27853651
Adoptive T-cell therapy (ACT) is an emerging paradigm in which T cells are genetically modified to target cancer-associated antigens and eradicate tumors. However, challenges treating epithelial cancers with ACT reflect...
5.
Goodwin J, Kothari V, Drake J, Zhao S, Dylgjeri E, Dean J, et al.
Cancer Cell
. 2015 Jul;
28(1):97-113.
PMID: 26175416
Emerging evidence demonstrates that the DNA repair kinase DNA-PKcs exerts divergent roles in transcriptional regulation of unsolved consequence. Here, in vitro and in vivo interrogation demonstrate that DNA-PKcs functions as...
6.
Magee M, Snook A
Discov Med
. 2014 Nov;
18(100):265-71.
PMID: 25425467
Chimeric antigen receptor (CAR)-expressing T cells have demonstrated potent clinical efficacy in patients with B cell malignancies. However, the use of CAR-T cell therapy targeting other cancers has, in part,...
7.
Marszalowicz G, Snook A, Magee M, Merlino D, Berman-Booty L, Waldman S
Oncotarget
. 2014 Oct;
5(19):9460-71.
PMID: 25294806
The emergence of targeted cancer therapy has been limited by the paucity of determinants which are tumor-specific and generally associated with disease, and have cell dynamics which effectively deploy cytotoxic...
8.
Witek M, Snook A, Lin J, Blomain E, Xiang B, Magee M, et al.
PLoS One
. 2014 Aug;
9(8):e104293.
PMID: 25101906
Gene expression is a dynamic and coordinated process coupling transcription with pre-mRNA processing. This regulation enables tissue-specific transcription factors to induce expression of specific transcripts that are subsequently amplified by...
9.
Snook A, Magee M, Schulz S, Waldman S
Eur J Immunol
. 2014 Apr;
44(7):1956-66.
PMID: 24771148
Self-tolerance, presumably through lineage-unbiased elimination of self-antigen-specific lymphocytes (CD4(+) T, CD8(+) T, and B cells), creates a formidable barrier to cancer immunotherapy. In contrast to this prevailing paradigm, we demonstrate...
10.
Witek M, Blomain E, Magee M, Xiang B, Waldman S, Snook A
Int J Radiat Oncol Biol Phys
. 2014 Mar;
88(5):1188-95.
PMID: 24661671
Purpose: Radiation therapy (RT) is thought to produce clinical responses in cancer patients, not only through direct toxicity to cancer cells and supporting tumor stroma cells, but also through activation...